Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03523728

A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients — STAGED-PKD  

Polycystic Kidney, Autosomal Dominant Clinical Trial

Official title:
Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Clinical Trial Summary

Primary Objective: To determine the effect of venglustat on the rate of total kidney volume (TKV) growth (Stage 1) and estimated glomerular filtration rate (eGFR) decline in participants at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Stage 2). Secondary Objectives: - To determine the effect of venglustat on the rate of renal function decline (Stage 1) and on the rate of TKV growth (Stage 2). - To evaluate the pharmacokinetics (PK) of venglustat in ADPKD participants (Stages 1 and 2). - To determine the effect of venglustat on pain and fatigue, based on participant reported diary (Stages 1 and 2). - Safety/tolerability objectives: - To characterize the safety profile of venglustat (Stages 1 and 2). - To evaluate the effect of venglustat on mood using Beck Depression Inventory II (BDI-II) (Stages 1 and 2). - To evaluate the effect of venglustat on the lens by ophthalmological examination (Stages 1 and 2).

Clinical Trial Description

Study duration per participant was 26 months (maximal) that included a screening period of 15 days, run-in period of 2 weeks, a 24-month treatment period, and a follow-up 30 days after final dose of investigational medicinal product (IMP). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03523728
Study type Interventional
Source Sanofi
Contact
Status Terminated
Phase Phase 2/Phase 3
Start date October 4, 2018
Completion date August 3, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04310319 - Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt N/A
Completed NCT04363554 - The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease N/A
Recruiting NCT05521191 - A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 1
Completed NCT03687554 - Effect of Venglustat in Patients With Renal Impairment Phase 1
Completed NCT00565097 - Lanreotide as Treatment of Polycystic Livers Phase 2/Phase 3
Completed NCT00410007 - The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease N/A
Completed NCT02251275 - Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Phase 3
Completed NCT01559363 - A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease Phase 1/Phase 2
Completed NCT02903511 - Feasibility Study of Metformin Therapy in ADPKD Phase 2
Completed NCT00456365 - Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 3
Recruiting NCT05510115 - Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 2
Completed NCT02494141 - Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD Phase 4
Completed NCT04407481 - PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
Completed NCT02847624 - Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
Completed NCT03342742 - Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease N/A
Completed NCT02656017 - Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease Phase 2
Completed NCT04023214 - The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease
Terminated NCT01589705 - The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease N/A
Completed NCT00426153 - Octreotide in Severe Polycystic Liver Disease Phase 2/Phase 3
Completed NCT04534985 - Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease N/A